Salman Bushra Mustafa, Ayaad Omar, Ibrahim Rawan, AlHatrushi Manal Salim, Majed Mohamad, Al Zadjali Razzan, AlTobi Zainab Abdullah, Atabani Abier, AlHasani Ghalia Mubarak, AlMusheifri Malouk Nasser, El Kholy Mohamed Ibrahim, Al Sheedi Sara, AlHasni Nabiha Said, Al-Hashar Amna Khamis, Al-Awaisi Huda Shinoon, Al-Baimani Khalid
Pharmacy Department, National hematology and bone marrow transplant center, University Medical City , Muscat, Oman.
Quality and Accreditation Department, Sultan Qaboos Comprehensive Cancer Care and Research Centre (SQCCCRC), University Medical City, Muscat, Oman.
Asian Pac J Cancer Prev. 2025 Jan 1;26(1):269-277. doi: 10.31557/APJCP.2025.26.1.269.
This project aimed to minimize medication errors and improve safe medication administration in an oncology setting in Muscat, Oman.
The study, spanning from the second quarter of 2022 to the first quarter of 2023, employed a one-group pretest-posttest quasi-experimental design, assessing key performance indicators (medication error and medication administration errors rates per 1000 patient days) on quarterly basis before and after implementing targeted interventions. Interventions focused on medication management processes and Healthcare Informatics System (HIS), Environment and equipment, and Education The project utilized the FOCUS PDCA (find, organize, clarify, understand, select, plan, do, check and act) methodology. Ethical clearance was obtained from the Institutional Review Board.
The results showed significant reductions were observed in both medication error and medication administration error rates following the implementation of interventions. Specifically, the medication error rate decreased from 12.59 in the Second Quarter of 2022 (pre-intervention) to 5.26 in the Fourth Quarter of 2023 (post-intervention), with an overall ANOVA F-value of 9.2950 (p = 0.035). Similarly, the medication administration error rate declined from 5.39 to 1.29 over the same period, resulting in an ANOVA F-value of 8.2320 (p = 0.044).
The study indicates a significant improvement in patient safety outcomes following the intervention implementation, underscoring the effectiveness of the interventions in reducing medication errors and administration errors.
本项目旨在将阿曼马斯喀特一家肿瘤治疗机构的用药错误降至最低，并改善安全用药管理。
该研究从2022年第二季度持续至2023年第一季度，采用单组前后测准实验设计，在实施针对性干预前后，每季度评估关键绩效指标（每1000个患者日的用药错误和给药错误率）。干预措施聚焦于用药管理流程、医疗信息系统（HIS）、环境与设备以及教育。该项目采用了FOCUS PDCA（发现、组织、澄清、理解、选择、计划、执行、检查和行动）方法。已获得机构审查委员会的伦理批准。
结果显示，实施干预后，用药错误率和给药错误率均显著降低。具体而言，用药错误率从2022年第二季度（干预前）的12.59降至2023年第四季度（干预后）的5.26，总体方差分析F值为9.2950（p = 0.035）。同样，同期给药错误率从5.39降至1.29，方差分析F值为8.2320（p = 0.044）。
该研究表明，实施干预后患者安全结果有显著改善，强调了这些干预措施在减少用药错误和给药错误方面的有效性。
